<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2016-05-52-59</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-1325</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>БРОНХОПУЛЬМОНОЛОГИЯ, ЛОР, АЛЛЕРГОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BRONCHOPULMONOLOGY, ENT, ALLERGOLOGY</subject></subj-group></article-categories><title-group><article-title>Лекарственно-индуцированные интерстициальные поражения легких</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трофименко</surname><given-names>И. Н.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черняк</surname><given-names>Б. А.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Иркутская государственная медицинская академия последипломного образования Минздрава России</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2016</year></pub-date><volume>0</volume><issue>5</issue><fpage>52</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Трофименко И.Н., Черняк Б.А., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Трофименко И.Н., Черняк Б.А.</copyright-holder><copyright-holder xml:lang="en">Трофименко И.Н., Черняк Б.А.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/1325">https://www.med-sovet.pro/jour/article/view/1325</self-uri><abstract><p>Лекарственно-индуцированные интерстициальные поражения легких (ЛИИПЛ) являются одной из наиболее частых форм лекарственных пневмопатий. ЛИИПЛ составляют около 3% в структуре всей интерстициальной патологии легких, и это требует такого же диагностического подхода, как и при интерстициальных заболеваниях легких другого генеза или идиопатических интерстициальных пневмониях. Лекарственные средства (ЛС) индуцируют различные варианты поражения паренхимы легких, нередко сочетая в себе несколько патогистологических паттернов. ЛИИПЛ чаще протекают изолированно, однако пневмопатии могут быть и частью системных патологических процессов, индуцированных ЛС. Характерных клинических, гистологических и радиологических особенностей для абсолютного большинства ЛИИПЛ не существует, что обусловливает гиподиагностику лекарственных пневмопатий. Основным диагностическим критерием ЛИИПЛ является хронологическая зависимость между приемом ЛС и возникновением клинических проявлений. Диагностические трудности нередко обусловлены поздней клинико-рентгенологической манифестацией (длительный период времени от начала приема ЛС или после его отмены) либо отсутствием улучшения состояния после прекращения приема потенциально «виновного» ЛС. Однако своевременная диагностика ЛИИПЛ представляется чрезвычайно важной, поскольку во многих случаях отмена препарата способствует купированию и разрешению патологического процесса. </p></abstract><kwd-group xml:lang="ru"><kwd>лекарственно-индуцированные поражения легких</kwd><kwd>интерстициальные заболевания легких</kwd><kwd>пневмотоксичность</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Camus P, Bonniaud P. Drug-induced respiratory disease. In: Palange P, Simonds AK, editors. ERS handbook Respiratory Medicine 2nd edition. European Respiratory Society: Charlesworth Press, 2013, 399-410.</mixed-citation><mixed-citation xml:lang="en">Camus P, Bonniaud P. Drug-induced respiratory disease. In: Palange P, Simonds AK, editors. ERS handbook Respiratory Medicine 2nd edition. European Respiratory Society: Charlesworth Press, 2013, 399-410.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Camus P, Rosenow EC III, editors. Drug-induced and iatrogenic respiratory disease. London MPG Books, 2010.</mixed-citation><mixed-citation xml:lang="en">Camus P, Rosenow EC III, editors. Drug-induced and iatrogenic respiratory disease. London MPG Books, 2010.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ben-Noun L. Drug-induced respiratory disorders: incidence, prevention and management. Drug Saf, 2000, 23(2): 143-164.</mixed-citation><mixed-citation xml:lang="en">Ben-Noun L. Drug-induced respiratory disorders: incidence, prevention and management. Drug Saf, 2000, 23(2): 143-164.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug Induced Interstitial Lung Disease. Open Respir Med J, 2012, 6: 63-74.</mixed-citation><mixed-citation xml:lang="en">Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug Induced Interstitial Lung Disease. Open Respir Med J, 2012, 6: 63-74.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. British Journal of Cancer, 2004, 91: 18-23.</mixed-citation><mixed-citation xml:lang="en">Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. British Journal of Cancer, 2004, 91: 18-23.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Черняк Б.А., Воржева И.И. Лекарственно-индуцированные легочные эозинофилии. Рос сийский аллергологический журнал, 2011, 4: 5-22.</mixed-citation><mixed-citation xml:lang="en">Черняк Б.А., Воржева И.И. Лекарственно-индуцированные легочные эозинофилии. Рос сийский аллергологический журнал, 2011, 4: 5-22.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Camus P, Foucher P.The Drug-Induced Respiratory Disease Website. 2012. Available from: http://www.pneumotox.com</mixed-citation><mixed-citation xml:lang="en">Camus P, Foucher P.The Drug-Induced Respiratory Disease Website. 2012. Available from: http://www.pneumotox.com</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Matsuno O. Drug-induced interstitial lung dis￾ease: mechanisms and best diagnostic approaches. Respiratory Research, 2012, 13: 39. Available from: http://respiratory-research.com/ content/13/1/39</mixed-citation><mixed-citation xml:lang="en">Matsuno O. Drug-induced interstitial lung dis￾ease: mechanisms and best diagnostic approaches. Respiratory Research, 2012, 13: 39. Available from: http://respiratory-research.com/ content/13/1/39</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ryrfeldt A. Drug-induced inflammatory responses to the lung. Toxicol Lett, 2000, 112- 113: 171-176.</mixed-citation><mixed-citation xml:lang="en">Ryrfeldt A. Drug-induced inflammatory responses to the lung. Toxicol Lett, 2000, 112- 113: 171-176.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations. Radiographics, 2000, 20: 1245-1259.</mixed-citation><mixed-citation xml:lang="en">Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations. Radiographics, 2000, 20: 1245-1259.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Schnyder B, Pichler WJ. Mechanisms of drug￾induced allergy. Mayo Clin Proc, 2009, 84: 268-272.</mixed-citation><mixed-citation xml:lang="en">Schnyder B, Pichler WJ. Mechanisms of drug￾induced allergy. Mayo Clin Proc, 2009, 84: 268-272.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial Lung Disease Induced by Drugs and Radiation. Respiration, 2004, 71(4): 301-326.</mixed-citation><mixed-citation xml:lang="en">Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial Lung Disease Induced by Drugs and Radiation. Respiration, 2004, 71(4): 301-326.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Prasad R, Gupta P, Singh A, Goel N. Drug induced pulmonary parenchymal disease. Drug Discov Ther, 2014, 8(6): 232-237.</mixed-citation><mixed-citation xml:lang="en">Prasad R, Gupta P, Singh A, Goel N. Drug induced pulmonary parenchymal disease. Drug Discov Ther, 2014, 8(6): 232-237.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Muller NL, White DA, Jiang H, Gemma А. Diagnosis and management of drug-associated interstitial lung disease. British Journal of Cancer, 2004, 91 (2): 24-30.</mixed-citation><mixed-citation xml:lang="en">Muller NL, White DA, Jiang H, Gemma А. Diagnosis and management of drug-associated interstitial lung disease. British Journal of Cancer, 2004, 91 (2): 24-30.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Maldonado F, Limper AH, Jett JR. Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment. 2015 Dec. Available from: http:// www.uptodate.com/contents/pulmonary-toxicity-associated-with-systemic-antineo-plastictherapy-clinical-presentation-diagnosis-and-treatment/.</mixed-citation><mixed-citation xml:lang="en">Maldonado F, Limper AH, Jett JR. Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment. 2015 Dec. Available from: http:// www.uptodate.com/contents/pulmonary-toxicity-associated-with-systemic-antineo-plastictherapy-clinical-presentation-diagnosis-and-treatment/.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Romagnoli M, Bigliazzi C, Casoni G, Chilosi M, Carloni A, Dubini A et al. The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis Vasc Diffuse Lung Dis, 2008, 25: 36-45.</mixed-citation><mixed-citation xml:lang="en">Romagnoli M, Bigliazzi C, Casoni G, Chilosi M, Carloni A, Dubini A et al. The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis Vasc Diffuse Lung Dis, 2008, 25: 36-45.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol, 2008, 66: 82-87.</mixed-citation><mixed-citation xml:lang="en">Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol, 2008, 66: 82-87.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Schwaiblmair M, Berghaus T, Haeckel T, et al. Amiodarone-induced pulmonary toxicity: an underrecognized and severe adverse effect? Clin Res Cardiol, 2010, 99: 693-700.</mixed-citation><mixed-citation xml:lang="en">Schwaiblmair M, Berghaus T, Haeckel T, et al. Amiodarone-induced pulmonary toxicity: an underrecognized and severe adverse effect? Clin Res Cardiol, 2010, 99: 693-700.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">King TE. Amiodarone pulmonary toxicity. 2015 Dec. Available from: http://www.uptodate.com/ contents/amiodarone-pulmonary-toxicity/.</mixed-citation><mixed-citation xml:lang="en">King TE. Amiodarone pulmonary toxicity. 2015 Dec. Available from: http://www.uptodate.com/ contents/amiodarone-pulmonary-toxicity/.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bedrossian CW, Warren CJ, Ohar J, Bhan R. Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol, 1997, 1(1): 47-56.</mixed-citation><mixed-citation xml:lang="en">Bedrossian CW, Warren CJ, Ohar J, Bhan R. Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol, 1997, 1(1): 47-56.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Larsen BT, Vaszar LT, Colby TV, Tazelaar HD. Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity. Am J Surg Pathol, 2012; 36: 509-516.</mixed-citation><mixed-citation xml:lang="en">Larsen BT, Vaszar LT, Colby TV, Tazelaar HD. Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity. Am J Surg Pathol, 2012; 36: 509-516.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Valle JM, Alvarez D, Antunez J, Valdes L. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: a rare aetiology. Eur Respir J, 1995, 8(3): 470-471.</mixed-citation><mixed-citation xml:lang="en">Valle JM, Alvarez D, Antunez J, Valdes L. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: a rare aetiology. Eur Respir J, 1995, 8(3): 470-471.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol, 1987, 18: 349-354.</mixed-citation><mixed-citation xml:lang="en">Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol, 1987, 18: 349-354.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Tanawuttiwat T, Harindhanavudhi T, Hanif S, Sahloul MZ. Amiodarone-induced alveolar haemorrhage: a rare complication of a common medication. Heart Lung Circ, 2010, 19: 435-437.</mixed-citation><mixed-citation xml:lang="en">Tanawuttiwat T, Harindhanavudhi T, Hanif S, Sahloul MZ. Amiodarone-induced alveolar haemorrhage: a rare complication of a common medication. Heart Lung Circ, 2010, 19: 435-437.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Borders CW 3rd, Bennett S, Mount C, Claassen SL. A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. Mil Med, 2012, 177(1): 118-120.</mixed-citation><mixed-citation xml:lang="en">Borders CW 3rd, Bennett S, Mount C, Claassen SL. A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. Mil Med, 2012, 177(1): 118-120.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Balk RA. Methotrexate-induced lung injury. 2015 Nov. Available from: http://www.uptodate.com/ contents/methotrexate-induced-lung-injury/.</mixed-citation><mixed-citation xml:lang="en">Balk RA. Methotrexate-induced lung injury. 2015 Nov. Available from: http://www.uptodate.com/ contents/methotrexate-induced-lung-injury/.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying antirheumatic drugs in clinical practice. QJM, 2001, 94: 309-319.</mixed-citation><mixed-citation xml:lang="en">Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying antirheumatic drugs in clinical practice. QJM, 2001, 94: 309-319.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes CJ. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol, 1996, 35: 441-445.</mixed-citation><mixed-citation xml:lang="en">Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes CJ. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol, 1996, 35: 441-445.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford), 2005, 44: 61-66.</mixed-citation><mixed-citation xml:lang="en">Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford), 2005, 44: 61-66.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum, 2004, 50(5): 1370-1382.</mixed-citation><mixed-citation xml:lang="en">Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum, 2004, 50(5): 1370-1382.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">St Clair EW, Rice JR, Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med, 1985, 145: 2035-2038.</mixed-citation><mixed-citation xml:lang="en">St Clair EW, Rice JR, Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med, 1985, 145: 2035-2038.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J, 2000, 15: 373-381.</mixed-citation><mixed-citation xml:lang="en">Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J, 2000, 15: 373-381.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Weinblatt ME. Methotrexate in rheumatoid arthritis: toxicity issues. Br J Rheumatol, 1996, 35: 403-405.</mixed-citation><mixed-citation xml:lang="en">Weinblatt ME. Methotrexate in rheumatoid arthritis: toxicity issues. Br J Rheumatol, 1996, 35: 403-405.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Veen MJ, Dekker JJ, Dinant HJ, Van Soesbergen RM, Bijlsma JW. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol, 1995, 22: 1766-1768.</mixed-citation><mixed-citation xml:lang="en">Van der Veen MJ, Dekker JJ, Dinant HJ, Van Soesbergen RM, Bijlsma JW. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol, 1995, 22: 1766-1768.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis, 2005, 64(4): iv 42-43.</mixed-citation><mixed-citation xml:lang="en">Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis, 2005, 64(4): iv 42-43.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum, 2014, 43: 613-626.</mixed-citation><mixed-citation xml:lang="en">Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum, 2014, 43: 613-626.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol, 2007, 34: 1151-1154.</mixed-citation><mixed-citation xml:lang="en">Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol, 2007, 34: 1151-1154.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Ostor AJ, Chilvers ER, Somerville MF, Lim AY, Lane SE, Crisp AJ et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol, 2006, 33(3): 622-628.</mixed-citation><mixed-citation xml:lang="en">Ostor AJ, Chilvers ER, Somerville MF, Lim AY, Lane SE, Crisp AJ et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol, 2006, 33(3): 622-628.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Tengstrand B, Ernestam S, Engvall IL, Rydvald Y, Hafstrom I. TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports. Lakartidningen, 2005, 102(49): 3788-3790.</mixed-citation><mixed-citation xml:lang="en">Tengstrand B, Ernestam S, Engvall IL, Rydvald Y, Hafstrom I. TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports. Lakartidningen, 2005, 102(49): 3788-3790.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Liote H, Liote F, Seroussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: A systematic literature review. Eur Respir J, 2010, 35: 681-687.</mixed-citation><mixed-citation xml:lang="en">Liote H, Liote F, Seroussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: A systematic literature review. Eur Respir J, 2010, 35: 681-687.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M. et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum, 2007, 56(4): 1125-1133.</mixed-citation><mixed-citation xml:lang="en">Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M. et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum, 2007, 56(4): 1125-1133.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Lake FR. Drug-induced lung disease in rheumatoid arthritis. 2015 Nov. Available from: http:// www.uptodate.com/contents/drug-inducedlung-disease-in-rheumatoid-arthritis/</mixed-citation><mixed-citation xml:lang="en">Lake FR. Drug-induced lung disease in rheumatoid arthritis. 2015 Nov. Available from: http:// www.uptodate.com/contents/drug-inducedlung-disease-in-rheumatoid-arthritis/</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
